PRE- FEASIBILITY REPORT - Welcome to...
Transcript of PRE- FEASIBILITY REPORT - Welcome to...
PRE- FEASIBILITY REPORT OF
M/S. SYMED LABS LIMITED, UNIT -I FLAT NO: 8-3-166/7/1,
SREE ARCADE, 2ND FLOOR,
ERRAGADDA, HYDERABAD - 500 018,
TELANGANA STATE.
EXPANSION OF
BULK DRUG MANUFACTURING UNIT -I
At
SURVEY NO. 353, DOMADUGU VILLAGE, BONTHAPALLY IDA,
JINNARAM MANDAL, MEDAK DISTRICT
TELANGANA STATE
Contents
S. No. Description Page no. 1.0 Executive Summary 1 2.0 Introduction of The Proposed Project 2 2.1 Project Proponent 2 2.2 Brief description of nature of the project. 2
2.3 Need for the project and its importance to the country and or region 2
2.4 Demand-Supply Gap. 3
2.5 Employment Generation(Direct and Indirect) due to the project 5
3.0 Project description 6 3.1 Products and Production Capacity 8 3.2 Raw materials required and Quantities 8 -12 3.3 Manufacturing Process 13 3.4 Resource – Utilize and Recycling 13
3.4.1 Water 13
3.4.2 Power Requirement 14
3.4.3 Fuel Requirement 14 3.5 Quantity of wastes to be generated 14
3.5.1 Waste Water Generation and utilization 14 3.5.2 Solid waste generation and Disposal 15
3.6 Schematic representations of the feasibility drawing which give information of EIA purpose. 16
4.0 Site Analysis 17 4.1 Connectivity 17 4.2 Land Form, Land use and Land ownership. 17 4.3 Existing Infrastructure 17 4.4 Soil classification 17 4.5 Climatic data from secondary sources. 17 4.6 Social Infrastructure available. 18 5.0 Planning brief 18 6.0 Proposed infrastructure 18 6.1 Industrial Area 18 6.2 Residential Area 18 6.3 Green Belt: 18 6.4 Social Infrastructure 18
6.5 Water management 19 6.6 Sewerage System 19 6.7 Industrial Waste Management 19 7.0 Rehabilitation and Resettlement (R&R) Plan 19 8.0 Project Schedule and Cost estimates 19 9.0 Analysis of project 19
LIST OF TABLES
Table No Description Page no. 3.1 Proposed Products and Quantities 8 3.2 Raw Materials For Carvedilol 9 3.3 Raw Materials For Fluconazole 9 3.4 Raw Materials For Itopride Hydrochloride 9 3.5 RAW MATERIALS FOR Ketrolac Tromethamine 10 3.6 Raw Materials For Levocetirizine Dihydrochloride 10 3.7 Raw Materials For Levosulpride 10 3.8 Raw Materials For Linezolid 11 3.9 Raw Materials For Mosapride Citrate Dihydrate 11
3.10 Raw Materials For Pregabalin 11 3.11 Raw Materials For Thalidomide 12 3.12 Raw Materials For Tizanidine Hydrochloride 12 3.13 Raw Materials For Topiramate 12 3.14 Water Requirement Details 14 3.15 Wastewater generation and Treatment Method 15 3.16 Solid waste generation and Disposal 15
LIST OF FIGURES
Figure No Description Page no. 1.1 Location Map 7
LIST OF FLOW CHART
Flow Chart No Description Page no. 3.1 Generalized Flow Chart for Bulk Drug
Manufacturing 12
Pre- Feasibility Report
M/S. SYMED LABS LIMITED Unit -I. 1
1.0 EXECUTIVE SUMMARY
M/s. Symed Labs Limited is limited company registered on 17 August, 1998 with
registered address at Flat No: 8-3-166/7/1, Sree Arcade, 2nd Floor, Erragadda,
Hyderabad - 500 018 to produce bulk drugs and bulk drug intermediates
The company has 5 number of bulk drug and intermediate manufacturing units in
Telangana State and the present proposal is to expand its manufacturing unit –I
capacity located at Sy.No. 353, Domadugu Village, Bonthapally IDA, Jinnaram
Mandal of Medak District (DT), Telangana State.
S. No Parameter Description
1 Project Location
Sy.No. 353, Domadugu Village, Bonthapally IDA, Jinnaram Mandal of Medak District, Telangana State
2
Category of Project as per EIA Notification & Amendments 5(f) “A”
3 Project cost 2.0 Crores (proposed) 4 Plot area 3.26 Acres
5 Proposed Product Proposed Products List is mentioned in section 3.1 6 Resources
(i)Electricity Requirement
Source of electricity SPDCL
D. G. Sets 500 KVA D.G Set Existing. 320 KVA DG set for Proposed Expansion
(ii)Water consumption 167 .24 KLD Source of water IDA Waste water generation 45.77KLD Mode of disposal Zero Liquid Discharge System
(iii)Boiler 2.0TPH Existing 3.0 TPH Proposed
(iV)Fuel
Coal - 5.0 MT / Day Existing Requirement Coal - 7.5 MT /Day for proposed boiler Requirement
7 Solid waste generation Mentioned in Para 3.5.1 of report
8 Nearest Highway State Highway No.6 -0.4 KMs ORR (outer ring Road – 8.5 KMs
9 Nearest Railway Station Medchal railway station – 11.40 KMs 10 Nearest Air Port Rajeev Gandhi International Air port- 47.5 KMs
Pre- Feasibility Report
M/S. SYMED LABS LIMITED Unit -I. 2
2.0 INTRODUCTION OF THE PROJECT M/s. Symed Labs Limited has its Bulk Drugs and Intermediates manufacturing unit
-I at Sy.No. 353, Domadugu Village, Bonthapally IDA, Jinnaram Mandal of Medak
District, Telangana State.
2.1 Project Proponent M/s. Symed Labs Limited was registered on 17 August, 1998 with registered
address Flat No: 8-3-166/7/1, Sree Arcade, 2nd Floor, Erragadda, and Hyderabad -
500 018, Telangana State, India.
Mr. D. Mohan Rao is Managing Director of the Company and he is Doctorate in
science having more than 28 years of extensive operational experience in the area
of API’s process developments and commercialization.
Mr. M. V Nandachary is Director, have experience in bulk drug industries more
than 25 years.
2.2 Brief description of nature of the project.
The proposed expansion is to manufacture Bulk Drugs and intermediate, which are
active ingredients with medicinal properties.
2.3 Need for the project and its importance to the country and or region
The company is engaged in the manufacturing of bulk drugs & intermediates and is
planning to increase its capacity.
The project in general holds significance for an emerging country like India where
health care costs are increasing by the day due to demand supply gap in affordable
medicines. Moreover due to low cost and hi technology the bulk drugs manufactured
in India has immense export potential with consequent possibility of foreign
exchange earnings
Pre- Feasibility Report
M/S. SYMED LABS LIMITED Unit -I. 3
Hyderabad has emerged as major drug manufacture city with a presence in global
market. Pharma industry in the state contribute more than one third to the country’s
total production.
Most of the companies have set up their R&D facilities in the state, thus making the
state the pharmaceutical capital of the country.
Hyderabad has developed as a major production center for bulk drugs due to the
location if the many major Pharmaceutical Industries such as Dr. Reddy’s
Laboratories, Aurobindo Pharma, Neuland Laboratories, Siris, Hetaro Drugs, Divis
Labs, Natco Pharma Limited, Matrix Labs, Nicholas Piramal etc., besides a large
number of medium and small industries manufacturing bulk drugs of all kinds.
In support of this growth in Hyderabad and Bangalore, many basic chemical units
and drug intermediate units have also come up to meet the input requirements of
Bulk Drug manufacturing Companies. Large numbers of these units are still
dependent on supply of basic chemicals mainly from Mumbai, Gujarat and other
parts of the country involving heavy expenditure on transport and transit risks.
2.3 Demand-Supply Gap.
The demand for APIs and API intermediates is a derived demand. It gets derived
from the demand for various medicinal formulations (final administrable drugs) for
the formulation industry.
The APIs and API intermediates being manufactured by basic drug
manufacturers are exported as such or used by domestic formulators in their
production processes. The formulation firms further produce final medicines
and export these as well as sell these in the domestic market.
There is a wide gap in the demand and availability of cheap and quality
medicines in India and the world over.
Generic medicines and off patent drugs have significant potential to increase
access to cheap and effective medicines to poor people and in general to
bridge the demand supply gap.
Pre- Feasibility Report
M/S. SYMED LABS LIMITED Unit -I. 4
Indian basic drug manufacturers are playing a significant role in increasing
access to affordable off patent drugs.
The products envisaged include third generation antibiotics, anticancer,
antipsychotic, etc drugs which address the problems associated with present
day stressful lifestyles and demand for these outstrips their demand and is
increasing by the day.
Pharmaceutical Industry – Domestic Scenario The Indian Pharmaceutical Industry today is in the front rank of India’s Science-
based industries with wide ranging capabilities in the complex field of drug
manufacture and technology. The Indian Pharmaceutical industry is estimated to be
worth US $ 8.0 billions at present, growing at a CAGR of over 15 % annually. If
India‘ s high Economic growth rate holds steady, the pharmaceuticals market will
triple to $ 24 billion by 2015 and become one of the world` s top 10 markets
according to a study by McKinsey and company ,a leading management
consulting firm. At a compounded annual growth rate of 15.0 %, the absolute
growth of $ 24 billion will be next to the growth potential of the US and China, and in
the same league as the growth in Japan and Canada and the UK. Five factors will
drive the growth of the Indian Pharmaceuticals market over the next decade;
Doubling of disposable incomes and the increase in numbers of middle class
households , significant expansion of medical infrastructure, greater penetration of
health insurance, a gradual shift in disease profile and adoption of patented
products, and finally population growth.
It ranks very high in the third world, in terms of technology, quality and range of
medicines manufactured. Playing a key role in promoting and sustaining
development in the vital field of medicines, the Indian Pharmaceutical Industry
boasts of quality producers and many units approved by regulatory authorities in
USA and UK.
The Indian Pharmaceutical sector has more than 20,000 registered units. It has
expanded drastically in the last two decades. The leading 250 pharmaceutical
Companies control 70% of the market. The pharmaceutical industry in India meets
Pre- Feasibility Report
M/S. SYMED LABS LIMITED Unit -I. 5
around 70% of the country’s demand for bulk drugs, drugs intermediates,
pharmaceutical formulations, chemicals, tablets, capsules, orals and injectables.
There are about 250 large units and about 8000 small Scale Units, which form the
core of the pharmaceutical industry in India (including 5 Central Public Sector Units).
These units produce the complete range of pharmaceutical formulations, i.e.
medicines ready for consumption by patients and about 350 bulk drugs, i.e.
chemicals having therapeutic value and used for production of pharmaceutical
formulations.
2.4 Employment Generation (Direct and Indirect) due to the project
The project will employ permanent as well as contractual and sub-contractual
employees from surrounding areas. Estimated employment generation is 40 (Direct)
employees. Apart from this there will be significant non estimated employment
generation at the supplier firms and service industry providing services to the
company. Company shall be giving preference to people from economically weaker
sections for employment in various semi-skilled/unskilled jobs thereby contributing to
their upliftment.
It is expected to direct or indirect employ about 50 people of various skills will be
required during construction as well as operation phase. The Details of employment
shown in below Table.
Particulars Existing Employees
Employees after Expansion
Functional Area
Key managerial staff
4 8 Finance,Marketing, Production, Quality control, R&D, Logistics etc.
Administration 8 20 Office work Skilled and semi skilled
28 52 Production Process, Maintenance, stores, Safety.& Un skilled workers
Total 40 80
Pre- Feasibility Report
M/S. SYMED LABS LIMITED Unit -I. 6
3.0 Project Description
M/s. Symed Labs Limited. Unit -I proposes for expansion manufacturing of
products at Survey No.353, IDA, Bonthapally, Domadugu (V),Jinnaram (M), Medak
(Dt), - 502319. Telangana State. The Location map is shown at Figure – 1.
The site coordinates are Latitude: 170 39’36.1” North
Longitude: 780 22’ 12.6”East
The site well connected to road and rail way line. No archaeological, historical sites
located nearby. Therefore, the project site does not offer any negative impact on the
local area as because it is an expansion of existing unit in notified industrial area, but
rather has a positive impact on socio economic conditions of the habitants around it.
The proposed plant is well connected both to State Highway No– 6 and Railway line
at Limgampally Railway Station. A total of about 13207.88 SQMs of land is required
for the project.
Pre- Feasibility Report
M/S. SYMED LABS LIMITED Unit -I. 7
Figure 1.1: Location Map
Survey No.353, IDA, Bonthapally, Domadugu (V),Jinnaram (M), Medak (Dt), - 502319.
Pre- Feasibility Report
M/S. SYMED LABS LIMITED Unit -I. 8
3.1 Products and Production Capacity
M/s. Symed Labs Limited Unit - I. proposes for expansion to produce the below
mentioned shown in Table3.1.
Table3.1: Proposed Products and Quantities
S. No Name of the Product CAS No’s Quantity In Kg/Month
Quantity In Kg/Day
1 Carvedilol 72956-09-3 2000.00 66.67 2 Fluconazole 86386-73-4 2000.00 66.67 3 Itopride Hydrochloride 122892-31-3 5000.00 166.67 4 Ketrolac tromethamine 74103-06-3 4000.00 133.33 5 Levocetirizine
Dihydrochloride 130018-87-0 1000.00 33.33
6 Levosulpride 23672-07-3 500.00 16.67 7 Linezolid 165800-03-3 5000.00 166.67 8 Mosapride Citrate
Dihydrate
636582-62-2 200.00 6.67
9 Pregabalin 148553-50-8 5000.00 166.67 10 Thalidomide 50-35-1 50.00 1.67 11 Tizanidine Hydrochloride 64461-82-1 50.00 1.67 12 Topiramate 97240-79-4 500.00 16.67
Total 23000.00 766.67 (Worst combination of any 6 products)
3.2 Raw materials required and Quantities All the raw materials required for manufacturing of above products will be sourced
from local market. The products wise required raw materials and quantities are
shown in below Tables 3.2-3.13.
TABLE3.2: RAW MATERIALS FOR CARVEDILOL
S. No Raw Material Consumption/ Batch in Kgs
Consumption/ Day in Kgs
1 4(Oxiranyl methoxy)-9H-Carbazole 32.50 39.39 2 (2-methoxyphenoxy)ethylamine 22.50 27.27 3 Ethyl acetate 413.00 500.56 4 Methanol 395.00 478.74 5 Activated carbon 7.00 8.48
Pre- Feasibility Report
M/S. SYMED LABS LIMITED Unit -I. 9
TABLE3.3: RAW MATERIALS FOR FLUCONAZOLE
S. No Raw Material Consumption/
Batch in Kgs Consumption/
Day in Kgs 1 1[2-(2,4-Difluorophenyl)-2,3-epoxy
propyl)-1H-1,2,4-Triazole 77.45 51.63
2 1,2,4-Triazole 45.10 30.07 3 Potassium carbonate 130.00 86.67 4 Acetone 630.00 420.00 5 Ethyl acetate 1076.00 717.33 6 Activated carbon 10.00 6.67
TABLE3.4: RAW MATERIALS FOR ITOPRIDE HYDROCHLORIDE
S. No Raw Material Consumption/ Batch in Kgs
Consumption/ Day in Kgs
1 3,4-Dimethoxybenzoic acid 42.89 76.86 2 Thionyl chloride 28.01 50.19 3 4-(N,N-di methyl amino ethoxy)
benzyl amine 45.73 81.95
4 Hydrochloric acid 10.50 18.82 5 Aq. Ammonia 159.00 284.93 6 IPA.HCl 94.00 168.45 7 Toluene 1478.00 2648.58 8 Chloroform 449.00 804.61 9 IPA 943.00 1689.86
10 Methanol 506.00 906.75 11 Activated carbon 16.00 28.67
TABLE3.5: RAW MATERIALS FOR KETOROLAC TROMETHAMINE
S. No Raw Material Consumption/ Batch in Kgs
Consumption/ Day in Kgs
1 Ketrolac 69.86 90.42 2 Tromethamine 33.14 42.89 3 Activated carbon 13.00 16.83 4 Methanol 265.00 343.00 5 Acetone 2278.00 2948.49
Pre- Feasibility Report
M/S. SYMED LABS LIMITED Unit -I. 10
TABLE3.6: RAW MATERIALS FOR LEVOCETIRIZINE DIHYDROCHLORIDE
S. No Raw Material Consumption/ Batch in Kgs
Consumption/ Day in Kgs
1 1-[((4-Chlorophenyl)phenyl)methyl]-4-[(phenylsulphonyl)]piperazine
46.20 30.80
2 2(2-Chloroethoxy )acetamide 14.90 9.93 3 4-Hydroxy benzoic acid 16.00 10.67 4 Hydrobromic acid 8.80 5.87 5 Sodium hydroxide 8.70 5.80 6 Hydrochloric acid 15.80 10.53 7 Sodium carbonate 11.50 7.67 8 Potassium iodide 1.70 1.13 9 Toluene 1515.00 1010.00
10 MDC 1860.00 1240.00 11 Acetone 465.00 310.00 12 Activated carbon 4.00 2.67
TABLE3.7: RAW MATERIALS FOR LEVOSULPRIDE
S. No Raw Material Consumption/ Batch in Kgs
Consumption/ Day in Kgs
1 Methyl-2-methoxy-5-sulfamoyl benzoate
97.68 11.98
2 1-Ethyl-2-amino methyl pyrrolidine 51.06 6.26 3 Ethylene glycol 290.00 35.57 4 Methanol 1900.00 233.07 5 Activated carbon 5.00 0.61
TABLE3.8: RAW MATERIALS FOR LINEZOLID
S. No Raw Material Consumption/ Batch in Kgs
Consumption/ Day in Kgs
1 N-[3-Phthalimido-2R-hydroxypropyl-3-fluoro-4-morpholinyl aniline
106.55 197.33
2 Carbonyl di imidazole 43.25 80.10 3 Hydrazine Hydrate 13.35 24.72 4 Acetic anhydride 27.23 50.43 5 Methanol 753.00 1394.56 6 MDC 2682.00 4967.06
Pre- Feasibility Report
M/S. SYMED LABS LIMITED Unit -I. 11
7 Activated carbon 10.80 20.00 8 Ethyl acetate 805.00 1490.86 9 Acetone 1548.00 2866.90
TABLE3.9: RAW MATERIALS FOR MOSAPRIDE CITRATE DIHYDRATE
S. No
Raw Material Consumption/ Batch in Kgs
Consumption/ Day in Kgs
1 2-Amino methyl-4-(4-fluorobenzyl)morpholine
25.87 2.30
2 4-Amino-5-chloro-2-ethoxy benzoic acid
24.87 2.21
3 Citric acid 22.16 1.97 4 Ethyl chloro formate 19.00 1.69 5 TEA 33.00 2.94 6 MDC 1865.00 165.99 7 Acetone 235.00 20.92 8 Methanol 210.00 18.69 9 Activated Carbon 16.00 1.42
TABLE3.10: RAW MATERIALS FOR PREGABALIN
S. No Raw Material Consumption/ Batch in Kgs
Consumption/ Day in Kgs
1 3-(Amino methyl)-5-methyl hexanoic acid
99.10 173.85
2 Mandelic acid 129.10 226.48 3 Liq. Ammonia 14.60 25.61 4 Citric acid monohydrate 74.60 130.87 5 Methanol 1464.00 2568.34 6 Activated carbon 8.00 14.03
TABLE3.11: RAW MATERIALS FOR THALIDOMIDE
S. No Raw Material Consumption/ Batch in Kgs
Consumption/ Day in Kgs
1 Phthalyl glutamic acid anhydride 30.11 1.68 2 Urea 6.97 0.39 3 Ethanol 584.00 32.51 4 N,N-DMF 468.00 26.05
Pre- Feasibility Report
M/S. SYMED LABS LIMITED Unit -I. 12
TABLE3.12: RAW MATERIALS FOR TIZANIDINE HYDROCHLORIDE
S. No Raw Material Consumption/ Batch in Kgs
Consumption/ Day in Kgs
1 4-Amino-5-chloro-2,1,3-benzo-thiadiazole
75.00 2.50
2 1-Acetyl-imidazolidin-2-one 52.00 1.73 3 Phosphorous oxy chloride 62.00 2.07 4 Sodium hydroxide 65.00 2.17 5 Methanol 5530.00 184.33 6 Activated carbon 155.00 5.17 7 Hydrochloric acid 14.80 0.49
TABLE3.13: RAW MATERIALS FOR TOPIRAMATE
S. No Raw Material Consumption/ Batch in Kgs
Consumption/ Day in Kgs
1 D-Fructose 50.00 33.33 2 Acetone 317.00 211.33 3 Sulfuric acid 55.00 36.67 4 Sodium hydroxide 38.00 25.33 5 Isopropyl alcohol 12.00 8.00 6 n-Hexane 83.00 55.33 7 Sulfuryl chloride 53.00 35.33 8 Ammonia 3.26 2.17 9 Sodium hydroxide 20.00 13.33
10 Pyridine 34.00 22.67 11 Citric acid 25.00 16.67 12 Sodium carbonate 25.00 16.67 13 Hydrochloric acid 19.00 12.67 14 MDC 665.00 443.33 15 Toluene 1740.00 1160.00 16 Ethyl acetate 270.00 180.00 17 IPA 115.00 76.67 18 Activated carbon 4.00 2.67
Pre- Feasibility Report
M/S. SYMED LABS LIMITED Unit -I. 13
3.3 Manufacturing Process
The manufacturing process of bulk drugs consists of chemical synthesis extending
to stages of processing involving different type of chemical reactions. The
generalized Flow chart for bulk drug manufacturing is shown in Flow chart 3.1.
Flow Chart 3.1: Generalized Flow Chart for Bulk Drug Manufacturing
3.4 Resource – Utilize & Recycling 3.4.1 Water Water requirement of the project for domestic and industrial activity during operation
phase will be 167.24 KLD. The water requirement will be met through IDA. The
detailed water requirement shown in below Table3.14. Table 3.14: WATER REQUIREMENT DETAILS
S. No Purpose Water Consumption
In KLD 1 Process 9.24 2 Washings 5.00 3 Boiler Make up 30.00
Pre- Feasibility Report
M/S. SYMED LABS LIMITED Unit -I. 14
4 Cooling towers Make up 110.00 5 DM Plant 3.00 6 Scrubbing system 1.00 7 Domestic 3.00 8 Gardening 6.00
Total 167.24
3.4.2 Power Requirement Power requirement of proposed project will be made available through APCPDCL.
Total power requirement of proposed plant shall be 1000 KVA
One No’s of D. G. sets of capacity 500 KVA are available to meet emergency power
requirement of the plant, 320 KVA DG Set will be installed for proposed expansion.
3.4.3 Fuel Requirement
2.0 TPH Capacity Boiler is in use for plant operations and proposed to install 3.0
TPH Boiler for expansion and Total fuel requirement will be around 5.0 TPD and 7.5
TPD respectively is the coal requirement and Coal is procured form local sources. 3.5 Quantity of wastes to be generated
3.5.1 Waste Water Generation and utilization
Total effluent generated in the project is 45.77 KLD. The treated water will be reused
for plant operations.
The process waste water from Process, floor Washes, scrubbers, QC and R&D are
evaporated in MEE with stripper and ATFD after neutralization. The condensate from
MEE and ATFD will be collected and treated in effluents treatment plant along with
effluents from utilities followed by RO. RO rejects will be send back to MEE and RO
Permeate will be re-used back.
To treat the sewage generated due to domestic activities will be disposed through
septic tank following by soak pit.
Table3.15: Wastewater generation and Treatment Method
S. No
Purpose HTDS In KLD
LTDS In KLD
Effluent In KLD
Disposal Method
1 Process 9.76 0.01 9.77 HTDS Effluent sent to ETP with MEE 2 Washings 0.00 5.00 5.00
Pre- Feasibility Report
M/S. SYMED LABS LIMITED Unit -I. 15
3 Boiler Blow down 4.50 0.00 4.50 system. LTDS effluents treated in ETP-RO Rejects to ME system and RO permeate to reuse, Condensate from MEE to reuse and MEE residue to AFTD.
4 Cooling towers Blow down
0.00 20.00 20.00
5 DM Plant 3.00 0.00 3.00 6 Scrubbing system 1.00 0.00 1.00
7 Domestic 0.00 2.50 2.50 Septic tank followed by Soak pit
Total 18.26 27.51 45.77
3.5.2Solid waste generation and Disposal
The types of Hazardous and non Hazardous wastes generated from the project,
method of disposal is shown in below table3.16. Table 3.16: Solid waste generation and Disposal
S. No Description Quantity
In Kg/Day Method Of Disposal
1. Organic solid Waste 68.00 Sent to TSDF/Cement Industries 2. Inorganic solid waste 87.00 Sent to TSDF 3. Spent Carbon 95.00 Sent to TSDF/Cement Industries 4. ETP Sludge 70.00 Sent to TSDF 5. Coal ash from Boiler 5875.00 Sent to Brick Manufacturers 6. Evaporation salts 889.00 Sent to TSDF 7. Spent solvents 23098.00 Recovery & Reuse 8. Distillation Bottom Residue 30.00 Sent to TSDF 9. Waste Oils & Grease 50 Ltrs/Annum APPCB Authorized Agencies for
Reprocessing/Recycling 10. Detoxified Containers 1000
No’s/Month After Detoxification sent back to suppliers/APPCB Authorized Parties
11. Used Lead Acid Batteries 5 No’s/Year Send back to suppliers for buyback of New Batteries
Pre- Feasibility Report
M/S. SYMED LABS LIMITED Unit -I. 16
3.6 Schematic representations of the feasibility drawing which give information of EIA purpose.
The applicability of the S.O 1533 for the proposed project was explored by
considering different possibilities & provision made in the said notification.
Considering the products & project location of the proposed project it is noticed that
the proposed project falls under Category 5 (f) “A” of the Schedule-I of EIA
Notification SO 1533.
As per the provision of the SO 1533, it is necessary to get Environmental Clearance
by applying to MoEF along with the Environmental Impacts Assessment Study
Report for the proposed project prior to commissioning of the project activities.
Therefore the EIA is required to conduct to comply with provisions of SO 1533 made
for Category 5(f) “B” of schedule –I of the notification.
Pre- Feasibility Report
M/S. SYMED LABS LIMITED Unit -I. 17
4.0Site Analysis
4.1 Connectivity
M/s Symed Labs Limited Unit -I is having well developed road and Rail way line
Connections for transportation of raw materials and finished products .
The nearest habitation from the site is domadugu at a distance of 0.1Km.
The nearest railway station is Medchal Railway station at a distance of 11.40
KMs from the site.
The nearest airport is Rajeev Gandhi International Air port at a distance of
47.4 KMs at Samshabad, Hyderabad.
The Nearest road ways
State Highway No.6 (Hyderabad- Narsapur Road) – 0.4KMs
4.2 Land Form, Land use and Land ownership. The proposed expansion is in existing area only and located in Notified Industrial
Area.
There would be no any change in Land Use, Land Cover or Topography of plot. After
implementation of project a dense green belt would be developed.
4.3 Existing Infrastructure. Proposed project is a expansion within existing facility and the basic infrastructure is already there. 4.4 Soil classification The district is mainly covered by three types of soils Sandy Loan, Black clay Loam,
Laterate types of soil.
4.5 Climatic data from secondary sources. Temperature Maximum: 46.3o C Minimum: 24 o C
Normal annual rainfall 811.9 mm 4.6 Social Infrastructure available.
Well developed social infrastructure facilities are available at nearby Habitations.
Pre- Feasibility Report
M/S. SYMED LABS LIMITED Unit -I. 18
5.0 Planning Brief
Proposed plant expansion activities will be started after getting statutory clearance
form related authorities. The project will be completed within two years.
Further proposed project activities will take care of all the rules and regulation of
statutory authority and provide the control measure and devices to achieve the
standard norms.
6.0 Proposed Infrastructure 6.1 Industrial Area
Basic infrastructure developed already and the required plant and machineries will
be installed after getting statutory clearance.
6.2 Residential Area
No residential area is involved in the proposed project. The employs are accommodated in nearby Residential areas 6.3 Green Belt: Approximately 33 % of Green Belt will be provided and maintained. 6.4 Social Infrastructure: Facilities like road and communication are good..Banks, ATM's and medical facilities are also adequate. Amenities: Education- schools including middle, secondary and higher secondary schools, social welfare hostels. Medical and Health- Community Health Centre, & Primary Health center Are available near villages Power and water- All the villages are electrified and drinking water facilities are extended to all villages.
Pre- Feasibility Report
M/S. SYMED LABS LIMITED Unit -I. 19
Rail and Road- The project site is very well connected by road through National Highway no. 9, Southern railways. 6.5 Water management Water requirement will be fulfilled through Industrial Development Authority. 6.6 Sewerage System: There will be no discharge of industrial effluent (Zero Liquid Discharge). The treated effluent will be reused. Domestic waste water will be disposed off through soak pit system.
6.7 Industrial Waste Management:
Due to proposed project, the effluent from cooling and Plant/Equipment washing will
be generated and treated in the well designed Effluent Treatment Plant. The treated
effluent will be reused.
7.0 Rehabilitation and Resettlement (R & R) Plan
Rehabilitation & Resettlement (R&R) plan is not applicable to proposed project.
8.0 Project Schedule & Cost Estimates
Proposed project activities will be started after getting statutory clearance form
related authorities. The cost of the proposed expansion will be approximately 2.0
Crores the project will be completed within two years.
9.0 Analysis of proposal (Final Recommendations)
Proposed expansion activity will provide benefits to the local people in terms of
financial and social welfare.
Local people will get direct financial benefit by way of employment.
Local people will get some contracts of supply and services to get indirect
income.
Company will contribute in improving education and health facilities in nearby
area.